Most Read Articles
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Exploring the potential of targeted therapy for haematological malignancies

13 Feb 2020
The development of imatinib, a tyrosine kinase inhibitor (TKI), has revolutionised the treatment landscape of chronic myeloid leukaemia (CML); the 10-year survival rate of patients who received imatinib was 83.3%.1,2 Current ELN guidelines recommend either imatinib, nilotinib or dasatinib as first-line treatment for patients with CML.3 Owing to the development of resistance, lack of response or intolerance to imatinib, a proportion of patients initially treated with imatinib will require an alternative therapy.4,5 Moreover, while achieving an early molecular response (EMR; ie, BCR-ABL1IS ≤10% at 3 months) with TKI has been associated with a higher probability of achieving deep molecular response (DMR), the rate of EMR failure is higher with imatinib than nilotinib – a second-generation TKI.6,7
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.